BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it raised $150 million in ...
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 17,007,044 | $979,945,875 | -1% | 2.88% |
| 2. | 193,400 | $11,143,708 | -25% | 0.04% | |
| 3. | Motley Fool Asset Management Bryan Hinmon | 175,529 | $10,113,981 | -1% | 0.39% |
| 4. | Fisher Asset Management Ken Fisher | 173,404 | $9,991,553 | -15% | 0% |
| 5. | Skylands Capital Charles Paquelet | 138,725 | $7,993,335 | -2% | 0.98% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.05 | 4,481 | $278,046.05 | 159,248 | 2026-04-01 | Filing | |
| $61.60 | 25,519 | $1,571,970.40 | 163,729 | 2026-04-01 | Filing | |
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 180,384,994 | $10,393,783,402 | 0.15% | |
| 2. | 102,408,940 | $5,900,803,123 | 0.18% | |
| 3. | 21,821,384 | $1,257,348,170 | 0.21% | |
| 4. | 10,168,924 | $585,933,423 | 0.33% | |
| 5. | 10,143,181 | $584,450,089 | 0.17% |
News See All
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol-Myers Squi...
AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal
British drugmaker AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) are in early talks about a potential merger that could create a $40...
Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?
Shares in biotechnology company Replimune ($REPL) soared over 120% in pre-market trading today after U.S. regulators gave the thumbs up to its skin...
Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
Cliff Asness is a billionaire investor and the co-founder and chief investment officer of AQR Capital Management, a quantitative hedge fund.
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?
TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential risks for companies, including ...
12 Best Low-Priced Pharma Stocks to Buy Right Now
Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies.
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
On May 27, Reuters reported that Biohub, a philanthropic venture formed by Meta CEO Mark Zuckerberg and Dr. Priscilla Chan, developed a global model of protein biology to speed up drug discovery.
12 Most Undervalued Stocks to Invest In
Undervalued stocks are getting more attention as investors look for opportunities outside the crowded growth trade.
Hedge Fund Resource Center